HCA Warning & Leqembi Shift

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics are particularly telling about the current pressures in the system.

MarcusSame here. We're looking at HCA's profit warning and what it signals for access in US hospitals. Then the subcutaneous Leqembi approval and its HEOR implications. And the FTC settlement with CVS Caremark over insulin pricing.

SaraThat second one on Leqembi is interesting to me — the administration shift could be a game-changer for value assessments, but we need to see the cost implications.

MarcusExactly. And the FTC settlement is a direct hit on PBM practices. Let's get into it.

MarcusHCA's profit warning is a stark signal. They're citing 'access erosion' and rising costs, specifically pointing to drug price inflation and complex reimbursement as key pressure points on hospital margins. This isn't just financial noise—it suggests systemic access challenges are hitting bottom lines.

SaraAnd what's striking here is the direct link between hospital viability and patient access. When hospitals face margin pressure, they're more likely to restrict high-cost drug access or shift costs to patients. That's the budget impact reality we've been tracking.

MarcusExactly. It connects to something I keep coming back to: the IRA's inflation rebates haven't addressed hospital-level financial strain. HCA's warning suggests the rebate system isn't filtering down to the point of care in a meaningful way. We're seeing a real decoupling between federal policy and operational reality.

SaraThat's fair, though I think payers would see it differently. The issue isn't just drug prices—it's the entire reimbursement ecosystem. Hospitals are getting squeezed from multiple angles: drug costs, staffing shortages, and administrative complexity. The FTC settlement we'll discuss next actually targets one of those angles.

MarcusI wonder if that's the full picture though. The HCA statement specifically mentions 'rising costs' and 'access erosion' in the same breath, implying causation. Historically, hospital margins have absorbed price increases, but now they're passing them through. That's a structural shift worth watching.

SaraThe part that gives me pause is how this plays out for vulnerable populations. If hospitals restrict access to high-cost drugs, it's not just about budget impact—it's about equitable access. We need more granular data on which therapies are being targeted.

MarcusAbsolutely. Now, shifting to subcutaneous Leqembi—this approval could fundamentally alter the Alzheimer's landscape. Moving from IV to subcutaneous administration reduces infusion time from hours to minutes, which improves patient experience and lowers logistical burdens. For HEOR, this shifts the value proposition toward convenience and real-world adherence.

SaraAnd that's where the cost-effectiveness analysis gets tricky. The drug itself is still priced at the same level, but the administration cost savings are substantial. We'll need to model the total cost of care impact—especially for caregivers and healthcare systems. The IV administration was a significant barrier for many patients.

MarcusRight, and from the payer side, the reduction in infusion time could lower facility fees and caregiver time costs. But we don't yet have real-world evidence on adherence rates. Will patients actually stick with subcutaneous dosing as prescribed? That's a key HEOR question for the next wave of evidence generation.

SaraWhat strikes me about that is the precedent this sets. If subcutaneous formulations become the norm for biologics, it could reshape how we evaluate value—shifting focus from pure efficacy to total system burden. We may need new PROs to capture administration burden.

MarcusI'd push back slightly on that. The value framework remains the same—it's about QALYs and cost-effectiveness. But the inputs change. Lower administration burden could translate to higher adherence, which improves outcomes. That's the chain we need to model. The FDA approval itself doesn't change the ICER assessment, but the evidence landscape will.

SaraThat's one read—I'd frame it slightly differently. The subcutaneous route expands the treatable population to those who couldn't tolerate IV infusions. That's a population-level access shift, not just a convenience factor. The HTA bodies will need to adjust their decision trees accordingly.

MarcusExactly. Now, the FTC settlement with CVS Caremark—this is a landmark moment. The $100 million settlement addresses allegations that CVS inflated insulin costs for patients through pharmacy benefit manager practices. It mandates pricing transparency and changes to how insulin is reimbursed.

SaraAnd what matters here is the precedent for PBM accountability. The settlement directly targets the 'spread pricing' practice where PBMs charge patients more than the negotiated rate. This could force PBMs to operate with more transparency, which would benefit both patients and payers.

MarcusThat's fair, though I think payers would see it differently. The real impact is on formulary access. If PBMs can no longer inflate costs, they might be more selective about which insulin products they cover. That could create formulary access hurdles for new entrants. We've seen this pattern before with biologics.

SaraThe part that gives me pause is whether this actually reduces patient costs. The settlement requires CVS to pay $100 million, but without specific caps on insulin prices, the system-wide impact is unclear. This feels like a procedural fix rather than a structural solution to affordability.

MarcusI wonder if that's the full picture though. The FTC's action signals a regulatory shift toward PBM oversight. If this becomes a trend, it could reshape how PBMs negotiate rebates and pass savings to patients. That's a market access game-changer for insulin manufacturers. We need to watch for copycat actions.

SaraFinally, ICER's expansion of early-phase scientific advice—this is a strategic move. They're broadening the program to cover more diseases and endpoints, aiming to help sponsors design trials with HTA-relevant evidence earlier. The goal is to reduce the evidence gap at launch.

MarcusAnd what's interesting here is the timing. With the IRA accelerating price negotiations, sponsors need HTA-aligned evidence sooner. ICER is essentially filling a gap by providing early-stage guidance that wasn't available before. This could streamline the entire value demonstration process.

SaraThat's one read—I'd frame it slightly differently. The expansion reflects a recognition that traditional endpoints don't always capture real-world value. By including more endpoints earlier, ICER is pushing sponsors to think about patient-centric outcomes from the outset. That's a fundamental shift in trial design.

MarcusRight, and from the payer side, this could reduce the need for post-launch RWE generation. If the trial already addresses HTA concerns, payers can make faster decisions. But we'll need to see if the advice actually influences trial protocols. Historically, sponsors have been reluctant to change late-stage trials based on HTA feedback.

SaraWhat strikes me about that is the resource implications. Sponsors now have to balance regulatory requirements with HTA advice. The question is whether ICER's program becomes a de facto requirement for launch planning. That could create new evidence-generation costs.

SaraA lot to think about today. I'll be watching how the FTC settlement impacts PBM practices and insulin access, and whether ICER's advice actually translates to trial design changes.

MarcusSame — and for me the thread running through today is the growing tension between innovation and system sustainability. HCA's warning, Leqembi's administration shift, FTC's PBM action, and ICER's advice all point to a system under pressure. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.